Humana experienced a significant surge in its share price, climbing 15% on Friday, following projections that position the health insurer as a leading beneficiary of the upcoming 2027 Medicare Advantage star ratings. This marks a dramatic reversal of fortunes for the company, which had faced considerable pressure in recent years.

The insurer announced that an impressive 95% of its Medicare Advantage members are expected to be enrolled in plans rated four stars or higher for 2027. This figure represents a monumental leap from just 20% in 2026 and comfortably surpasses analyst expectations, which had ranged between 60% and 70%. These elevated ratings from the U.S. health department are crucial, as they directly translate into billions of dollars in bonus payments from the government, significantly impacting an insurer’s financial health.

Analysts highlight that Humana’s projected ratings for 2027 are set to outshine those of its larger competitors. For instance, estimates suggest that UnitedHealth’s share of enrollments in plans rated four stars or higher will likely decrease to approximately 67% from 81%. Similarly, CVS Health is anticipated to see a decline in its highly-rated enrollments, falling to roughly 70% from 84%. This competitive advantage underscores Humana’s strong position in the evolving Medicare Advantage landscape.

This turnaround is particularly noteworthy given Humana’s recent struggles. The company had been under scrutiny since a steep drop in its 2025 ratings threatened its bonus payments, compounded by a lost lawsuit challenging the 2025 rating calculations last October and a 2026 profit forecast that fell below Wall Street estimates in February. Evercore ISI analyst Elizabeth Anderson attributed the sharp improvement to advancements in measures of drug-plan quality, health-plan quality, and readmissions, suggesting the insurer could receive an estimated $4.8 billion in bonus payments in 2028. While Baird analysts noted that the ultimate boost to profits would depend on strategic reinvestment in member benefits and arrangements with healthcare providers, the current outlook is overwhelmingly positive for one of the largest providers of Medicare Advantage plans.

Overall, the U.S. health department reported that approximately 71% of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027, indicating a general trend of quality improvement across the sector, with Humana leading the charge.

Key Takeaways

• Humana's shares surged 15% following projections that it will be a top beneficiary of the 2027 Medicare Advantage star ratings.
• A remarkable 95% of Humana's Medicare Advantage members are expected to be in plans rated four stars or higher for 2027, a significant increase from 20% in 2026.
• This dramatic improvement positions Humana for billions in government bonus payments, contrasting with its recent struggles and outperforming major rivals like UnitedHealth and CVS Health in the upcoming ratings.

Editor’s Analysis & Impact

Humana’s impressive turnaround in Medicare Advantage star ratings has significant implications for the health insurance industry. This surge highlights the critical financial impact of these ratings, as higher scores directly translate into billions in government bonus payments. For Humana, this not only promises substantial revenue growth and improved profitability but also strengthens its competitive standing against larger rivals like UnitedHealth and CVS Health, who are projected to see declines in their highly-rated enrollments. The news could prompt competitors to intensify their focus on quality improvement initiatives to secure better ratings in future cycles. Broader implications include a potential shift in market share and investor confidence within the Medicare Advantage sector, underscoring the importance of quality metrics in a highly regulated and competitive environment.

Frequently Asked Questions

Q: What are Medicare Advantage star ratings?
A: Medicare Advantage star ratings are a system used by the U.S. health department to evaluate the quality and performance of Medicare Advantage plans. Plans are rated on a scale of 1 to 5 stars, with higher ratings indicating better quality and leading to significant bonus payments for insurers.

Q: How will Humana's improved ratings impact its finances?
A: The significantly improved 2027 star ratings qualify Humana for billions of dollars in government bonus payments. One analyst estimates the insurer could receive $4.8 billion in bonus payments in 2028, which would substantially boost its profitability and financial outlook.

Q: How does Humana's 2027 performance compare to its rivals?
A: Humana's projected 2027 ratings, with 95% of its Medicare Advantage members in four-star or higher plans, are expected to significantly outperform those of major rivals. UnitedHealth and CVS Health are both anticipated to see a decrease in their proportion of highly-rated enrollments for 2027.